A novel anticancer diarylurea derivative HL-40 as a multi-kinases inhibitor with good pharmacokinetics in Wistar rats.

@article{Lu2015ANA,
  title={A novel anticancer diarylurea derivative HL-40 as a multi-kinases inhibitor with good pharmacokinetics in Wistar rats.},
  author={Yu-Yin Lu and Cui-rong Zhao and Rui-qi Wang and Wen-bao Li and Xianjun Qu},
  journal={Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie},
  year={2015},
  volume={69},
  pages={255-9}
}
HL-40, N-(4-(1-(4-chlorine indazole)) phenyl)-N-(4-chloro-3-three fluorine methyl phenyl) urea, is a novel diarylurea derivative. In this study, we investigated the kinases activities and binding constants, pharmacokinetics of HL-40, and then evaluated its anticancer efficacy by both in vitro and in vivo methods. Enzyme activities assays in vitro were… CONTINUE READING